Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 14/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737969 | 0.92 | TRPV4 (0.43) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8737795 | 0.89 | TRPV4 (0.46) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8738809 | 0.88 | TRPV4 (0.45) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8738037 | 0.87 | TRPV4 (0.46) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8737775 | 0.87 | TRPV4 (0.44) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8737713 | 0.86 | TRPV4 (0.44) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8738410 | 0.86 | TRPV4 (0.43) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8737783 | 0.84 | TRPV4 (0.42) | TRPV4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8737778 | 0.84 | MEN1 (0.45) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6113997 | 0.83 | TDP1 (0.48) | MEN1ALDH1A1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012068209-A2 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, MMP2 | TRPV4 3344/4885MEN1 2298/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.